View All Images Adderall may affect your sex drive. Image courtesy: Adobe Stock Being distracted or losing focus is one of the symptoms of Attention-deficit ...

Glasgow, April 18, 2025 (GLOBE NEWSWIRE) -- Best Alternatives to Adderall 2025 : Legal and OTC product for Enhanced Cognitive Function - Noocube “Can I get my brain to perform at 100% of its ...

Lupins are a cottage-garden favourite, offering height and colour to borders in May and June. Lupin flowers are borne on upright stems with many impressive, pea-like blooms on each stem, and are loved ...

Pharmaceutical major Lupin Ltd.'s share price advanced in early trading hours on Thursday after brokerage firm Nomura maintained a 'buy' call on the company amid its drug patency litigation issue. The ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc., will launch a bioequivalent version of Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to ...

Lupin: The firm confirmed that a United States court has issued ... The drug is a bioequivalent and therapeutically equivalent to Adderall and the distribution of the same will begin in May 2025. AWL ...

Lupin, however, maintains it has a strong case ... Glenmark Pharmaceuticals will launch a generic version of Adderall in the US in May 2025. The product, used to treat ADHD, will be available ...

Astellas Pharma had filed a patent infringement case against Lupin’s generic products of ... equivalent to the reference listed drug Adderall tablets by Teva Women’s Health, Inc. Distribution ...

Lupin and Zydus Lifesciences shares fell by almost 7 per cent on Wednesday after losing a patent case in a US federal court involving Myrbetriq, a prescription medicine used to treat overactive ...

Astellas Pharma had filed a patent infringement case against Lupin’s generic products of Mirabegron ... and therapeutically equivalent to the reference listed drug Adderall tablets by Teva Women’s ...

Shares of Lupin Ltd. and Zydus Lifesciences Ltd. declined by as much as 8% on Wednesday, April 16, following a legal setback in the United States. The two Indian pharmaceutical companies lost a patent ...

Shares of Indian pharmaceutical majors Lupin Ltd. and Zydus Lifesciences Ltd. declined sharply on April 16 after a US Federal Court ruled in favour of Astellas Pharma in a key patent litigation case.